Christopher E. Touloukian

2.2k citations

23 papers · 1.8k indexed · 1 hit paper · h-index 16

Impact in

Immunology top 2%
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Psoriasis: Treatment and Pathogenesis
Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in

Immunology 16
- Immunotherapy and Immune Responses 16
- T-cell and B-cell Immunology 12
- Immune Cell Function and Interaction 5
Oncology 9
- CAR-T cell therapy research 4
- Cancer Immunotherapy and Biomarkers 3
- Cutaneous Melanoma Detection and Management 2

Co-authors: Nicholas P. Restifo Steven A. Rosenberg Kari R. Irvine Lionel Feigenbaum Deborah R. Surman Paul A. Antony Douglas C. Palmer Christian S. Hinrichs
Journals: Journal of Clinical Investigation (3 papers)The Journal of Immunology (3 papers)Journal of Immunotherapy (2 papers)Annals of Surgery (1 paper)Chemical Senses (1 paper)
Partner nations: United States Netherlands Australia

In The Last Decade

Christopher E. Touloukian

22 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Tumor-specific Th17-polarized cells eradicate large established melanoma 2008 · 638 citations

Peers

Countries citing papers authored by Christopher E. Touloukian

Since Specialization

Citations

This map shows the geographic impact of Christopher E. Touloukian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher E. Touloukian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher E. Touloukian more than expected).

Fields of papers citing papers by Christopher E. Touloukian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher E. Touloukian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher E. Touloukian. The network helps show where Christopher E. Touloukian may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher E. Touloukian, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher E. Touloukian Line = papers co-authored together Christopher E. Touloukian links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Chemotherapeutic Agents Subvert Tumor Immunity by Generating Agonists of Platelet-Activating Factor Cancer Research ·Ravi P. Sahu, Clement Osei Akoto, Kathleen A. Harrison, Matheus Ferracini, Christopher E. Touloukian, Mohammed Al‐Hassani, Drouhet, Mathew Loesch, Robert C. Murphy, Sandra K. Althouse, Susan M. Perkins, Paul J. Speicher, Douglas S. Tyler, Raymond L. Konger, Jeffrey B. Travers	2014	36
2	Impaired PIASy–Tip60 signaling weakens activation of p53 in melanoma Melanoma Research ·Alexander J. Lakhter, Sriramana Kanginakudru, Simon Warren, Christopher E. Touloukian, Raymond E. Boissy, Samisubbu R. Naidu	2013	6
3	The environmental stressor ultraviolet B radiation inhibits murine antitumor immunity through its ability to generate platelet-activating factor agonists Carcinogenesis ·Ravi P. Sahu, Matthew J. Turner, Sonia C. DaSilva‐Arnold, G. Dadashi Zadeh, Clement Osei Akoto, Susan M. Perkins, Raymond L. Konger, Christopher E. Touloukian, Mark H. Kaplan, Jeffrey B. Travers	2012	49
4	Primary Teratoma of the Lesser Sac: Lesser Sac Teratoma SHILAP Revista de lepidopterología ·E. Orozco, Thomas M. Ulbright, Christopher E. Touloukian, Lawrence H. Einhorn	2012	0
5	Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity Journal of Clinical Investigation ·Tomáš Scholz, Nicholas D. Klemen, Garrett Kinnebrew, Andrew Brandmaier, Jon W. Marsh, Giao Hangoc, Douglas C. Palmer, Nicholas P. Restifo, Kenneth Cornetta, Hal E. Broxmeyer, Christopher E. Touloukian	2010	18
6	High-avidity Autoreactive CD4+ T Cells Induce Host CTL, Overcome Tregs and Mediate Tumor Destruction Journal of Immunotherapy ·Andrew Brandmaier, Wolfgang W. Leitner, Tomáš Scholz, John Sidney, Nicholas P. Restifo, Christopher E. Touloukian	2009	15
7	Cutaneous Melanoma, 5th Edition Annals of Surgery ·Christopher E. Touloukian	2009	3
8	Tumor-specific Th17-polarized cells eradicate large established melanoma Blood ·Pawel Muranski, Andrea Boni, Paul A. Antony, Lydie Cassard, Kari R. Irvine, Andrew Kaiser, Chrystal M. Paulos, Douglas C. Palmer, Christopher E. Touloukian, Krzysztof Ptak, Luca Gattinoni, Claudia Wrzesinski, Christian S. Hinrichs, Keith Kerstann, Lionel Feigenbaum, Chi‐Chao Chan, Nicholas P. Restifo Hit paper breakdown →	2008	638
9	Poor immunogenicity of a self/tumor antigen derives from peptide–MHC-I instability and is independent of tolerance Journal of Clinical Investigation ·Zhiya Yu, Marc R. Theoret, Christopher E. Touloukian, Deborah R. Surman, Scott C. Garman, Lionel Feigenbaum, Tiffany K. Baxter, Brian M. Baker, Nicholas P. Restifo	2004	102
10	Poor immunogenicity of a self/tumor antigen derives from peptide–MHC-I instability and is independent of tolerance Journal of Clinical Investigation ·Zhiya Yu, Marc R. Theoret, Christopher E. Touloukian, Deborah R. Surman, Scott C. Garman, Lionel Feigenbaum, Tiffany K. Baxter, Brian M. Baker, Nicholas P. Restifo	2004	100
11	Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1 The Journal of Immunology ·Christopher E. Touloukian, Wolfgang W. Leitner, Rhonda E. Schnur, Paul F. Robbins, Yong Li, Scott Southwood, Alessandro Sette, Steven A. Rosenberg, Nicholas P. Restifo	2003	18
12	Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens Journal of Immunotherapy ·Giao Q. Phan, Christopher E. Touloukian, James C. Yang, Nicholas P. Restifo, Richard M. Sherry, Patrick Hwu, Suzanne L. Topalian, Douglas J. Schwartzentruber, Claudia A. Seipp, 信太郎久尾, Kathleen E. Morton, Sharon Mavroukakis, Donald E. White, Steven A. Rosenberg	2003	91
13	Open left colon resection Kirk Ludwig, Christopher E. Touloukian	2003	2
14	Assumptions of the tumor ‘escape’ hypothesis Seminars in Cancer Biology ·Nicholas P. Restifo, Paul A. Antony, Steven E. Finkelstein, Wolfgang W. Leitner, Deborah R. Surman, Marc R. Theoret, Christopher E. Touloukian	2002	24
15	MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells Cancer Gene Therapy ·J. Mark Sloan, Michael H. Kershaw, Christopher E. Touloukian, Réjean Lapointe, Paul F. Robbins, Nicholas P. Restifo, Patrick Hwu	2002	24
16	Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen. PubMed ·Christopher E. Touloukian, Wolfgang W. Leitner, Paul Robbins, Steven A. Rosenberg, Nicholas P. Restifo	2001	16
17	A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute. PubMed ·Christopher E. Touloukian, Steven A. Rosenberg	2000	5
18	Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules The Journal of Immunology ·Gang Zeng, Christopher E. Touloukian, Xiang Wang, Nicholas P. Restifo, Steven A. Rosenberg, Rong‐Fu Wang	2000	123
19	Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens. PubMed ·Kari R. Irvine, Maria R. Parkhurst, 정혜 성, Janis P. Tupesis, Mary Custer, Christopher E. Touloukian, Paul F. Robbins, Alicia Gómez Yafal, Yeni Widyaningrum, Roger P.M. Sutmuller, Rienk Offringa, Steven A. Rosenberg, Nicholas P. Restifo	1999	33
20	Lotus Lectin Labels Subpopulation of Olfactory Receptor Cells Chemical Senses ·William Stewart, Christopher E. Touloukian	1996	11

About Christopher E. Touloukian

Christopher E. Touloukian is a scholar working on Immunology, Oncology, Sensory Systems, Molecular Biology and Psychiatry and Mental health, having authored 23 papers that have together received 1.8k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (16 papers), T-cell and B-cell Immunology (12 papers), vaccines and immunoinformatics approaches (6 papers), Immune Cell Function and Interaction (5 papers), CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cutaneous Melanoma Detection and Management (2 papers) and Autophagy in Disease and Therapy (1 paper). The work is most often cited by research in Immunology (1.5k citations), Oncology (838 citations), Molecular Biology (547 citations), Biotechnology (55 citations) and Genetics (155 citations). Christopher E. Touloukian has collaborated with scholars based in United States, Netherlands and Australia. Frequent co-authors include Nicholas P. Restifo, Steven A. Rosenberg, Kari R. Irvine, Lionel Feigenbaum, Deborah R. Surman, Paul A. Antony, Douglas C. Palmer, Christian S. Hinrichs, Lydie Cassard and Keith Kerstann. Their work appears in journals such as Journal of Clinical Investigation, The Journal of Immunology, Journal of Immunotherapy, Annals of Surgery and Chemical Senses.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact